Figure 4 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

• Methylation-based ctDNA changes predict long-term benefits from immune checkpoint inhibitors in patients with various cancers, leading to targeted therapies.
• In a subset of 75 patients, RECIST response predictably correlates with real-world progression-free survival (rwPFS) outcomes, enhancing prognostic capabilities.
• Analysis using Kaplan-Meier plots and forest models demonstrates significant predictive value of methylation responses, improving treatment decision-making.
• The findings suggest that combining ctDNA assessment with RECIST may enhance clinical outcomes for cancer patients undergoing immunotherapy.